In this webinar, Dr. Kristin G. Anderson, Research Associate from the Greenberg lab at the Fred Hutchinson Cancer Research Center, discusses engineering T cells to improve survival in the immunosuppressive tumor microenvironment.

Cell therapy is a transformative cancer treatment that utilizes genetically modified cells from a healthy donor or patient's own immune system to attack cancer cells, but manufacturing these cells represents a major challenge for the industry.

Most in vitro, well-plate biological experiments require a media change every day or two, with cyclic variations in nutrient and metabolite concentrations leading to physiologically unrealistic gene expression and metabolism.

In this session, Pall Corporation and Evello International will share their best practices on how to optimize your extraction and filtration process.

The involvement of lipids in many biological and physiological processes makes their analysis of paramount importance. Learn how MALDI-TIMS-MS imaging can facilitate the differentiation of isomeric lipid classes clearly, leading to confident lipid identification.

The AAA-ATPase p97 is an essential protein involved in numerous cellular processes and plays a key role in multiple aspects of protein homeostasis.

In this webinar, Kristina Schwamborn, associate professor in the Institute of Pathology at the Technical University of Munich, will discuss how MALDI-IMS can overcome the limitations of other approaches in the discovery and identification of new classifying marker molecules and profiles.

In this webinar, Dr George Poulogiannis from The Institute of Cancer Research, will discuss the relationship between oncogenic signaling and metabolic rewiring and explore cutting-edge technologies that can be used to track metabolism.

The emergence of molecular and genetic studies has increased our understanding of cytokines’ role in pathologic conditions. Treatments with biologic agents targeting either cytokine receptors, intracellular signaling, or specific cytokines improve some chronic inflammatory diseases’ symptoms.

CAR T-cell therapies are emerging anti-cancer treatments, whereby the patient’s immune cells are engineered to express chimeric antigen receptors (CARs) on their surface. Wider adoption of this therapeutic modality would benefit from innovative technologies that can improve the characterization of raw material quality attributes (MQA) and final product quality attributes (PQA).